By Iain Gilbert
Date: Friday 06 Feb 2026
(Sharecast News) - GSK revealed on Friday that non-executive chairman Jonathan Symonds had acquired 2,500 ordinary shres in the FTSE 100-listed drugmaker.
| Director/PDMR Shareholding | 06-Feb-2026 | 10:30 | RNS |
| Nucala COPD approved by the European Commission | 06-Feb-2026 | 07:00 | RNS |
| Director/PDMR Shareholding | 05-Feb-2026 | 15:30 | RNS |
| Final Results | 04-Feb-2026 | 07:00 | RNS |
| Total Voting Rights | 02-Feb-2026 | 15:00 | RNS |
| GSK beats City expectations but forecasts softer... | 04-Feb-2026 | Times |
| GSK looking at future cost savings and manufactu... | 02-Feb-2026 | Times |
| GlaxoSmithKline scraps sale of old drugs | 05-Dec-2014 | Telegraph |
| Glaxo sharpens axe to save £1bn as insurers and ... | 01-Dec-2014 | The Independent |
| GSK to cut hundreds of US jobs | 01-Dec-2014 | Telegraph |
| Questor :GlaxoSmithKline | 16-Apr-2014 | Telegraph |
| Questor:GlaxoSmithKline | 06-Oct-2011 | Telegraph |
| Questor:GlaxoSmithKline | 11-Aug-2011 | Telegraph |
| Questor tip: GlaxoSmithKline | 28-Jul-2011 | Telegraph |
| Investment Column: GlaxoSmithKline | 27-Jul-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 2,215.00p |
| Change Today | 17.00p |
| % Change | 0.77 % |
| 52 Week High | 2,219.00p |
| 52 Week Low | 1,264.00p |
| Volume | 1,533,462 |
| Shares Issued | 4,076.08m |
| Market Cap | £90,285m |
| Beta | 0.86 |
| RiskGrade | 129 |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Strong Buy | 4 |
| Buy | 3 |
| Neutral | 13 |
| Sell | 3 |
| Strong Sell | 0 |
| Total | 23 |

| Latest | Previous | |
|---|---|---|
| Q4 | Q3 | |
| Ex-Div | 19-Feb-26 | 13-Nov-25 |
| Paid | 09-Apr-26 | 08-Jan-26 |
| Amount | 18.00p | 16.00p |
| Time | Volume / Share Price |
| 10:14 | 0 @ 2,215.00p |
| 10:14 | 100 @ 2,214.54p |
| 10:13 | 1 @ 2,215.00p |
| 10:13 | 220 @ 2,214.48p |
| 10:13 | 0 @ 2,215.00p |
You are here: research